Understanding side effects of new cancer treatments using patient feedback
Official title: Use of Patient-Reported Outcomes in Understanding Symptomatic Adverse Events in Early-Phase Trials of Combination Treatments that Include Immune Checkpoint Inhibitors and Targeted Therapy
Funded at University of Tx Md Anderson Can Ctr · NIH-10989909 · Data updated 2026-11-12
This study is looking to hear from cancer patients about the side effects they experience while receiving combination treatments that include immune checkpoint inhibitors, so we can better understand and manage any unique challenges that come with these therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | June 5, 2019 |
| Project end | November 30, 2025 |
| Funding year | 2025 |
| Award (this year) | $196,781 |
| NIH project number | 5R01CA242565-06 |
| Project ID | NIH-10989909 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with advanced cancer who are receiving combination therapies that include immune checkpoint inhibitors.
✕Less likely to help
Patients who are not undergoing combination cancer therapies or those with early-stage cancer may not benefit from this research.
What this research studies
This research focuses on gathering information from patients about the side effects they experience while undergoing combination cancer treatments that include immune checkpoint inhibitors. By utilizing patient-reported outcomes, the study aims to identify and track immune-related adverse events (irAEs) associated with these therapies. The researchers will analyze data from early-phase clinical trials at a leading cancer center to better understand the safety profiles of these innovative treatments. This approach will help in managing and mitigating the unique toxicities that may arise from these combination therapies.
Why it matters
Potential benefit: If successful, this research could lead to improved management of side effects for patients undergoing advanced cancer treatments.
How similar studies have gone: Previous research has shown promise in using patient-reported outcomes to assess treatment side effects, indicating that this approach could yield valuable insights.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: George, Goldy C — University of Tx Md Anderson Can Ctr
- Study coordinator: George, Goldy C
Related research
Other NIH-funded projects on the same topics.
-
Integrative histo-genomic analysis to guide cancer risk and targeted therapies with interpretable AI
Researchers are developing an advanced AI-powered approach to map genetic and cellular patterns across breast and cervical cancers to help tailor treatments.
-
Targeted therapy for AML using DHODH inhibitors to boost differentiation and immune response
Aims to help adults with acute myeloid leukemia by using a special drug approach that makes cancer cells act more like normal blood cells and supports the immune system.
-
Understanding how immune checkpoint drugs can trigger inflammatory arthritis in cancer patients
This research looks at why some cancer patients develop inflammatory arthritis after PD-1 inhibitor therapy and what could be done to prevent it.
-
Gut bacteria that can make cancer immunotherapy less effective
This project will see if reducing chronic inflammation driven by certain gut bacteria can help immunotherapy work better for people whose cancers have stopped responding.
-
Adipome biomarkers in obese TNBC mice for targeted therapy
A study in mice explores how fat-derived particles called adipomes influence an aggressive breast cancer type, with the goal of guiding personalized therapies.
-
Enhancing HER2-targeted therapy for resistant breast cancer
This grant explores new ways to overcome resistance to HER2-targeted therapy in people with HER2-positive breast cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.